Importantly, inhibiting the interaction between Rab45/RASEF-L and ERK1/2 using a cell-permeable peptide that corresponded to the ERK1/2-interacting site of RASEF suppressed the growth of lung cancer cells. Here, MAPK3 is linked to lung carcinoma.